{"id":12174,"date":"2011-09-29T15:34:04","date_gmt":"2011-09-29T19:34:04","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=12174"},"modified":"2011-09-29T15:34:04","modified_gmt":"2011-09-29T19:34:04","slug":"meta-analysis-explores-real-world-cv-risk-of-nsaids","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/09\/29\/meta-analysis-explores-real-world-cv-risk-of-nsaids\/","title":{"rendered":"Meta-Analysis Explores Real World CV Risk of NSAIDs"},"content":{"rendered":"<p>A new meta-analysis sheds additional light on the cardiovascular risk of NSAIDs as used in the real world, including low doses of the most popular drugs, over short periods, and in low-risk populations.<\/p>\n<p><a href=\"http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1001098\">In a paper published online in <em>PLoS Medicine<\/em><\/a>,\u00a0Patricia McGettigan and David Henry analyzed data from 30 case-control studies including 184,946 CV events and 21 cohort studies with outcomes in more than 2.7 million people.<\/p>\n<p>Among the NSAIDs with extensive data, rofecoxib and diclofenac had the highest CV risk while ibuprofen and naproxen had the lowest risk:<\/p>\n<ul>\n<li>rofecoxib, 1.45 (95% CI 1.33-1.59)<\/li>\n<li>diclofenac, 1.40 (1.27-1.55<\/li>\n<li>ibuprofen, 1.18 (1.11-1.25)<\/li>\n<li>naproxen, 1.09 (1.02-1.16)<\/li>\n<\/ul>\n<div>The authors point out that diclofenac was associated with elevated risk even at over-the-counter doses and that etoricoxib &#8220;is similar to drugs that have been withdrawn because of safety concerns.&#8221;\u00a0 Indomethacin also showed high risk; the authors write that the drug &#8220;has a range of gastrointestinal and central nervous system effects that, combined with the evidence presented here on cardiovascular risk, should lead to questioning of its continued clinical use.&#8221;<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A new meta-analysis sheds additional light on the cardiovascular risk of NSAIDs as used in the real world, including low doses of the most popular drugs, over short periods, and in low-risk populations. In a paper published online in PLoS Medicine,\u00a0Patricia McGettigan and David Henry analyzed data from 30 case-control studies including 184,946 CV events [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[835,1003,1002,1004,836,650,1001],"class_list":["post-12174","post","type-post","status-publish","format-standard","hentry","category-general","tag-diclofenac","tag-etoricoxib","tag-ibuprofen","tag-indomethacin","tag-naproxen","tag-nsaids","tag-rofecoxib"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/12174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=12174"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/12174\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=12174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=12174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=12174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}